Atai receives 130 million euros

With the current financing round, the biotech company Atai is said to be worth 1.7 billion euros. The round was led by German investor Christian Angermayer.
The investment duo Peter Thiel and Christian Angermayer have struck again: the biotech company Atai Life Sciences received 130 million euros via Thiel Capital and the Apeiron Investment Group, Angermayer's family office. The venture capitalist Woodline Partners, which specializes in pharmaceutical investments, is a new addition.
The Berlin-based start-up Atai Life Sciences is researching the effects of psychedelic substances to combat mental illnesses such as depression or anxiety. The aim is to use the substances commercially as a therapy under medical supervision; Angermayer is one of the world's largest investors in this field.
According to insiders, Atai is valued at 1.7 billion euros and an IPO on the US tech exchange Nasdaq is planned for the second quarter of 2021, according to the news agency Reuters. Atai only received 100 million euros from investors in the fall of 2020.

Newsletter
Startups, stories and stats from the German startup ecosystem straight to your inbox. Subscribe with 2 clicks. Noice.
LinkedIn ConnectFYI: English edition available
Hello my friend, have you been stranded on the German edition of Startbase? At least your browser tells us, that you do not speak German - so maybe you would like to switch to the English edition instead?
FYI: Deutsche Edition verfügbar
Hallo mein Freund, du befindest dich auf der Englischen Edition der Startbase und laut deinem Browser sprichst du eigentlich auch Deutsch. Magst du die Sprache wechseln?